Metreleptin not checked
FollowEvery change as it happens, and a Monday email
Trials
2 active
3 in total · 2 in the EU
What this is
- How it works
- Leptin Analog FDA class
- How it’s given
- “Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency”In the company’s words, NCT06484868 on ClinicalTrials.gov
- Main trialPhase 4
- “This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy”In the company’s words, NCT06484868 on ClinicalTrials.gov
Other drugs for Familial Partial Lipodystrophy
- MibavademabRegeneron · Phase 3
Coming up2
- Feb 2028Phase 4 trial completes · ClinicalTrials.gov
- Mar 2028Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 9 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT05164341
- 9 NovCompletion date moved: 2026-07-21 to 2026-07-14 · ClinicalTrials.gov NCT05164341
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | Feb 2028 | Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy | |
| Phase 3Recruiting | Mar 2028 | Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy | |
| Phase 3Completed | 14 Jul 2026 | Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026